Several studies have investigated the prognostic significance of the ratio of T790M to major EGFR mutation at baseline in patients with advanced EGFR T790M-positive NSCLC receiving osimertinib and reported that a higher ratio is closely related to tumor shrinkage and favorable survival13,19. Here, EGFR is linked to non-small cell lung carcinoma.